Canadian Cancer Trials Group Bulletins

Group Administrators Office

Recent Publications

Canadian Cancer Trials Group IND.181 -- Canadian Cancer Trials Group Phase I Study of AT9283 Given as a 24 Hour Infusion on Days 1 and 8 Every Three Weeks in Patients with Advanced Incurable Malignancy

The purpose of this study was to assess safety and tolerability, and the pharmacokinetic and pharmacodynamic properties of AT9283 in patients with advanced, incurable solid tumours or non-Hodgkin's lymphoma. The investigators were able to determine that AT9283 was well tolerated and that the recommended phase II dose was 40 mg/m2/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers.

Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L. Canadian Cancer Trials Group IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies (ONLINE). Invest New Drugs 1-8, 2013.


Canadian Cancer Trials Group IND.203 -- A Phase I Study of SB939 in Pediatric Patients with Refractory Solid Tumours and Leukemia

The purpose of this study was to assess the toxicities and pharmacokinetics of pracinostat (SB939) and to determine the recommended phase II dose in children with refractory solid tumours. Investigators found that pracinostat was reasonably well tolerated in children and the recommended phase II dose to be 45 mg/m2.

This study was the first pediatric Investigational New Drug (IND) clinical trial conducted by the Canadian Cancer Trials Group in collaboration with the C17 Council, an organization whose mission is to improve health outcomes and quality of life for children and adolescents in Canada with cancer and blood disorders.

Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer 60: 1868-74, 2013.


Canadian Cancer Trials Group CO.20 (Quality of Life) -- A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbitux) Versus Placebo in Combination with Cetuximab (Erbitux) in Patients With K-Ras Wild Type Tumours Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

The results of this study, which found that the combination of cetuximab/brivanib alaninate worsened time to quality of life (QoL) deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer compared to cetuximab alone, are highlighted on ( Dr. Jolie Ringash, lead author for the study, says "It may be that when working with patients who cannot be cured, where maintaining quality of life is the focus, the least toxic therapy which can still suppress cancer progression, may be the best approach."

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ. Quality of life in patients with K-RAS wild-type colorectal cancer (ONLINE). Cancer 2013.


Canadian Cancer Trials Group HD.6 -- A Phase III Study of Radiotherapy or ABVD plus Radiotherapy versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease

Treatment options for patients with nonbulky stage IA-IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT), and chemotherapy with ABVD alone. There are no mature randomized data comparing ABVD with CMT using modern radiation techniques.

Results of the study show that CMT provides better disease control than ABVD alone, especially among those not achieving complete response after two cycles of ABVD. Within the follow-up duration evaluated, overall survivals were similar. Longer follow-up is required to understand the implications of radiation and chemotherapy-related late effects.

Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dorken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma (ONLINE). Ann Oncol 2013.